Literature DB >> 23757293

Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line.

H Artee Luchman, Charles Chesnelong, J Gregory Cairncross, Samuel Weiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23757293      PMCID： PMC3714156          DOI： 10.1093/neuonc/not064

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  3 in total

1.  An in vivo patient-derived model of endogenous IDH1-mutant glioma.

Authors:  H Artee Luchman; Owen D Stechishin; N Ha Dang; Michael D Blough; Charles Chesnelong; John J Kelly; Stephanie A Nguyen; Jennifer A Chan; Aalim M Weljie; J Gregory Cairncross; Samuel Weiss
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.

Authors:  Genglin Jin; Zachary J Reitman; Christopher G Duncan; Ivan Spasojevic; David M Gooden; B Ahmed Rasheed; Rui Yang; Giselle Y Lopez; Yiping He; Roger E McLendon; Darell D Bigner; Hai Yan
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

3.  The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.

Authors:  Patrick S Ward; Chao Lu; Justin R Cross; Omar Abdel-Wahab; Ross L Levine; Gary K Schwartz; Craig B Thompson
Journal:  J Biol Chem       Date:  2012-12-21       Impact factor: 5.486
  3 in total
  22 in total

1.  CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.

Authors:  Casey J Moure; Bill H Diplas; Lee H Chen; Rui Yang; Christopher J Pirozzi; Zhaohui Wang; Ivan Spasojevic; Matthew S Waitkus; Yiping He; Hai Yan
Journal:  Mol Cancer Res       Date:  2019-07-10       Impact factor: 5.852

2.  Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential.

Authors:  Patricia D B Tiburcio; David L Gillespie; Randy L Jensen; L Eric Huang
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

3.  Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.

Authors:  Tali Mazor; Charles Chesnelong; Aleksandr Pankov; Llewellyn E Jalbert; Chibo Hong; Josie Hayes; Ivan V Smirnov; Roxanne Marshall; Camila F Souza; Yaoqing Shen; Pavithra Viswanath; Houtan Noushmehr; Sabrina M Ronen; Steven J M Jones; Marco A Marra; J Gregory Cairncross; Arie Perry; Sarah J Nelson; Susan M Chang; Andrew W Bollen; Annette M Molinaro; Henrik Bengtsson; Adam B Olshen; Samuel Weiss; Joanna J Phillips; H Artee Luchman; Joseph F Costello
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-15       Impact factor: 11.205

4.  De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.

Authors:  Diana D Shi; Milan R Savani; Michael M Levitt; Adam C Wang; Jennifer E Endress; Cylaina E Bird; Joseph Buehler; Sylwia A Stopka; Michael S Regan; Yu-Fen Lin; Vinesh T Puliyappadamba; Wenhua Gao; Januka Khanal; Laura Evans; Joyce H Lee; Lei Guo; Yi Xiao; Min Xu; Bofu Huang; Rebecca B Jennings; Dennis M Bonal; Misty S Martin-Sandoval; Tammie Dang; Lauren C Gattie; Amy B Cameron; Sungwoo Lee; John M Asara; Harley I Kornblum; Tak W Mak; Ryan E Looper; Quang-De Nguyen; Sabina Signoretti; Stefan Gradl; Andreas Sutter; Michael Jeffers; Andreas Janzer; Mark A Lehrman; Lauren G Zacharias; Thomas P Mathews; Julie-Aurore Losman; Timothy E Richardson; Daniel P Cahill; Ralph J DeBerardinis; Keith L Ligon; Lin Xu; Peter Ly; Nathalie Y R Agar; Kalil G Abdullah; Isaac S Harris; William G Kaelin; Samuel K McBrayer
Journal:  Cancer Cell       Date:  2022-08-18       Impact factor: 38.585

5.  Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.

Authors:  Elavarasan Subramani; Marina Radoul; Chloe Najac; Georgios Batsios; Abigail R Molloy; Donghyun Hong; Anne Marie Gillespie; Romelyn Delos Santos; Pavithra Viswanath; Joseph F Costello; Russell O Pieper; Sabrina M Ronen
Journal:  Cancer Res       Date:  2020-09-21       Impact factor: 12.701

Review 6.  The implications of IDH mutations for cancer development and therapy.

Authors:  Christopher J Pirozzi; Hai Yan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

7.  Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.

Authors:  Brad Davis; Yaoqing Shen; Candice C Poon; H Artee Luchman; Owen D Stechishin; Carly S Pontifex; Wei Wu; John J Kelly; Michael D Blough
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

Review 8.  Pre-clinical tumor models of primary brain tumors: Challenges and opportunities.

Authors:  Farhana Akter; Brennan Simon; Nadine Leonie de Boer; Navid Redjal; Hiroaki Wakimoto; Khalid Shah
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-10-23       Impact factor: 10.680

9.  Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas.

Authors:  Victor Ruiz-Rodado; Tathiane M Malta; Tomohiro Seki; Adrian Lita; Tyrone Dowdy; Orieta Celiku; Alejandra Cavazos-Saldana; Aiguo Li; Yang Liu; Sue Han; Wei Zhang; Hua Song; Dionne Davis; Sunmin Lee; Jane B Trepel; Thais S Sabedot; Jeeva Munasinghe; Chunzhang Yang; Christel Herold-Mende; Mark R Gilbert; Murali Krishna Cherukuri; Houtan Noushmehr; Mioara Larion
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

10.  Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas.

Authors:  Andrés Cano-Galiano; Anais Oudin; Fred Fack; Maria-Francesca Allega; David Sumpton; Elena Martinez-Garcia; Gunnar Dittmar; Ann-Christin Hau; Alfonso De Falco; Christel Herold-Mende; Rolf Bjerkvig; Johannes Meiser; Saverio Tardito; Simone P Niclou
Journal:  Neurooncol Adv       Date:  2021-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.